Document And Entity Information	9 Months Ended
Document And Entity Information	Sep. 30, 2015	Oct. 30, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3
Entity Registrant Name	ACURA PHARMACEUTICALS, INC
Entity Central Index Key	0000786947
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ACUR
Entity Common Stock, Shares Outstanding		11,800,986

CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 3,324	$ 774
Marketable securities (Note 6)	11,929	11,322
Accounts receivable, net of allowances of $88 and $5	167	76
Accrued investment income	51	66
Inventories, net (Note 7)	74	304
Prepaid expenses and other current assets	488	471
Other current deferred assets	1	218
Total current assets	16,034	13,231
Property, plant and equipment, net (Note 8)	1,042	957
Intangible asset, net of accumulated amortization of $310 and $155 (Note 3)	1,690	1,845
Other assets	175	0
Total assets	18,941	16,033
Current liabilities:
Accounts payable	276	217
Accrued expenses (Note 9)	825	568
Other current liabilities	33	26
Accrued interest	62	70
Sales returns liability	173	0
Deferred revenue	0	353
Current maturities of long-term debt (Note 10)	2,470	1,758
Total current liabilities	3,839	2,992
Long-term debt, net of discount of $220 and $281, and debt issuance costs of $112 and $162 (Note 10)	6,038	7,799
Long-term portion of accrued interest	339	190
Total liabilities	10,216	10,981
Commitments and contingencies (Note 16)
Stockholders' equity:
Common stock: $.01 par value per share; 100,000 shares authorized, 11,801 and 9,770 shares issued and outstanding at 2015 and 2014, respectively	118	98
Additional paid-in capital	375,012	367,288
Accumulated deficit	(366,394)	(362,321)
Accumulated other comprehensive loss	(11)	(13)
Total stockholders' equity	8,725	5,052
Total liabilities and stockholders' equity	$ 18,941	$ 16,033

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Accounts receivable, net of allowances	$ 88	$ 5
Finite-lived intangible assets accumulated amortization	310	155
Long-term debt, net of debt discount	220	281
Debt Instrument Issuance Cost	$ 112	$ 162
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	100,000	100,000
Common stock, shares issued	11,801	9,770
Common stock, shares outstanding	11,801	9,770

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenues:
License fee revenue	$ 0	$ 0	$ 5,250	$ 0
Collaboration revenue	95	0	95	0
Royalty revenue	0	0	0	4
Product sales, net	115	145	563	218
Total revenues, net	210	145	5,908	222
Cost and expenses:
Cost of sales (excluding inventory write-down)	132	108	554	188
Inventory write-down (Note 7)	27	0	334	201
Research and development	432	955	1,907	3,674
Selling, marketing, general and administrative	2,024	1,728	6,404	5,903
Total costs and expenses	2,615	2,791	9,199	9,966
Operating loss	(2,405)	(2,646)	(3,291)	(9,744)
Non-Operating income (expense):
Investment income	39	46	110	143
Interest expense (Note 10)	(283)	(304)	(892)	(907)
Other expense	0	0	0	(5)
Total other expense, net	(244)	(258)	(782)	(769)
Loss before provision for income taxes	(2,649)	(2,904)	(4,073)	(10,513)
Provision for income taxes	0	0	0	0
Net loss	(2,649)	(2,904)	(4,073)	(10,513)
Other comprehensive income (loss):
Unrealized gains (losses) on securities	2	(44)	2	6
Total other comprehensive income (loss)	2	(44)	2	6
Comprehensive loss	$ (2,647)	$ (2,948)	$ (4,071)	$ (10,507)
Loss per share of common stock:
Basic	$ (0.23)	$ (0.3)	$ (0.39)	$ (1.08)
Diluted	$ (0.23)	$ (0.3)	$ (0.39)	$ (1.08)
Weighted average shares outstanding:
Basic	11,677	9,784	10,446	9,774
Diluted	11,677	9,784	10,446	9,774

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (USD $) In Thousands	Total	Common Stock	Additional paid-in capital	Accumulated deficit	Accumulated Other Comprehensive Income (Loss)
Balance at Dec. 31, 2014	$ 5,052	$ 98	$ 367,288	$ (362,321)	$ (13)
Balance (in shares) at Dec. 31, 2014		9,770
Net loss	(4,073)	0	0	(4,073)	0
Other comprehensive income (loss)	2	0	0	0	2
Share-based compensation	461	0	461	0	0
Net distribution of common stock pursuant to restricted stock unit award plan	1	1	0	0	0
Net distribution of common stock pursuant to restricted stock unit award plan (in shares)		19
Modification to warrants issued with promissory notes	33	0	33	0	0
Issuance of common stock under “at the market” offerings, net of offering costs of $8	217	0	217	0	0
Issuance of common stock under “at the market” offerings, net of offering costs of $8 (in shares)		54
Issuance of common stock under registered direct offering, net of offering costs of $603	7,032	19	7,013	0	0
Issuance of common stock under registered direct offering, net of offering costs of $603 (in shares)		1,958
Balance at Sep. 30, 2015	$ 8,725	$ 118	$ 375,012	$ (366,394)	$ (11)
Balance (in shares) at Sep. 30, 2015		11,801

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015
Direct Offering [Member]
Deferred Offering Costs	$ 603
Market Offering [Member]
Deferred Offering Costs	$ 8

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Cash Flows from Operating Activities:
Net loss	$ (4,073)	$ (10,513)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	92	90
Provision to reduce inventory to net realizable value	334	201
Provision for sales returns	253	0
Share-based compensation	461	716
Amortization of debt discount and debt issue costs	144	140
Amortization of bond premium in marketable securities	106	201
Amortization of intangible asset	155	0
Loss on sales of marketable securities	0	5
Loss on disposal of property and equipment	20	1
Changes in assets and liabilities:
Accounts receivable, net	(171)	62
Accrued investment income	15	28
Inventories	(104)	(353)
Prepaid expenses and other current assets	(17)	(183)
Other current deferred assets	217	46
Other assets	(175)	4
Accounts payable	59	(158)
Accrued expenses	257	1,087
Deferred revenue	(353)	(59)
Accrued interest - current and long term	141	0
Other current liabilities	7	0
Net cash used in operating activities	(2,632)	(8,685)
Cash Flows from Investing Activities:
Purchases of marketable securities	(3,523)	(2,203)
Proceeds from sale and maturities of marketable securities	2,811	2,424
Acquisition of product rights	0	(2,000)
Additions to property, plant and equipment	(211)	(105)
Proceeds from disposal of property and equipment	14	0
Net cash used in investing activities	(909)	(1,884)
Cash Flows from Financing Activities:
Proceeds from exercise of stock options	0	8
Proceeds from distribution of restricted stock units	1	1
Statutory minimum withholding taxes paid on the distribution of common stock pursuant to restricted stock unit plan and exercise of stock options	0	(529)
Proceeds from “at-the-market” offering	225	0
Proceeds from registered direct offering	7,636	0
Offering transaction costs	(611)	0
Principal payments on debt	(1,160)	0
Net cash provided by (used) in financing activities	6,091	(520)
Net increase (decrease) in cash and cash equivalents	2,550	(11,089)
Cash and cash equivalents at beginning of year	774	12,340
Cash and cash equivalents at end of period	3,324	1,251
Cash paid during the period for:
Interest	606	557
Income taxes	$ 0	$ 0

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) (USD $) In Thousands, except Per Share data, unless otherwise specified	9 Months Ended
	Sep. 30, 2015 Stock options	Sep. 30, 2014 Stock options	Sep. 30, 2014 Restricted Stock Units (RSUs) [Member]
Supplemental Disclosure of Noncash Financing Activities:
Equity based employee compensation granted		5	165
Common stock withheld in exercise costs in shares		3	1
Common stock withheld in exercise costs		$ 32	$ 7
Withholding of exercise cost in shares		1	63
Minimum statutory withholding payroll taxes withheld		$ 4	$ 525
Common Stock issued upon exercise		1	102

DESCRIPTION OF BUSINESS

9 Months Ended

Sep. 30, 2015

Description Of Business Disclosure [Abstract]

DESCRIPTION OF BUSINESS

NOTE 1 - DESCRIPTION OF BUSINESS

Acura Pharmaceuticals, Inc., a New York corporation, and its subsidiary (the “Company”, “We”, or “Our”) is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. We have discovered and developed three proprietary platform technologies which can be used to develop multiple products. Our Aversion® Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Oxaydo™ Tablets (formerly known as Oxecta®) (oxycodone HCl, CII), is the first approved product utilizing Aversion® in the United States. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation (collectively, “Egalet”) pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize Oxaydo. Oxaydo is currently approved by the U.S. Food and Drug Administration, or FDA, for marketing in the United States in 5mg and 7.5mg strengths. Egalet launched Oxaydo in the United States late in the third quarter of 2015. We have also developed Impede® Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. We launched our first Impede Technology product, Nexafed®, into the United States market in December 2012 and our Nexafed Sinus Pressure + Pain product in the United States in February 2015. We have multiple pseudoephedrine products in development utilizing our Impede Technology. On June 15, 2015, we and Bayer Healthcare LLC (“Bayer”) entered into a License and Development Agreement to provide Bayer with an exclusive worldwide license to our Impede Technology for an undisclosed methamphetamine resistant pseudoephedrine – containing product, and providing for our joint development of such product utilizing our Impede™ Technology for the U.S. market. Our third technology, Limitx, is designed to retard the release of active drug ingredients when an excess number of tablets are accidently or purposefully ingested. In August 2014, we were awarded a $300 thousand grant from the National Institute on Drug Abuse to advance early stage development of our Limitx technology, of which we have received $237 thousand of the grant through September 30, 2015.

Amounts presented have been rounded to the nearest thousand, where indicated, except share and per share data. The equity amounts and all share and per share data of the Company have been retroactively adjusted to reflect a one-for-five reverse stock split on August 28, 2015.

ACCOUNTING PRONOUNCEMENTS

9 Months Ended

Sep. 30, 2015

New Accounting Pronouncements and Changes in Accounting Principles [Abstract]

ACCOUNTING PRONOUNCEMENTS

NOTE 2 – ACCOUNTING PRONOUNCEMENTS

Revenue from Contracts with Customers

In May 2014, the FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP.

The standard is effective for annual periods beginning after December 15, 2017, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). We are currently evaluating the impact of our pending adoption of ASU 2014-09 on our consolidated financial statements and have not yet determined the method by which we will adopt the standard in 2018.

- Definition

The entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 13

-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Accounting Change

-URI http://asc.fasb.org/extlink&oid=6503790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Direct Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6510796

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Indirect Effects of a Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6515603

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Change in Accounting Principle

-URI http://asc.fasb.org/extlink&oid=6507316

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 270

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.10-01.(b)(6))

-URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Retrospective Application

-URI http://asc.fasb.org/extlink&oid=6523989

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 250

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794

+ Details

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

9 Months Ended

Sep. 30, 2015

Research and Development Disclosure [Abstract]

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT

NOTE 3 - LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS

Egalet Agreement

On January 7, 2015, we and Egalet entered into a Collaboration and License Agreement (the “Egalet Agreement”) to commercialize Aversion Oxycodone under the tradename Oxaydo. Oxaydo is approved by the FDA for marketing in the United States in 5 mg and 7.5 mg strengths. Under the terms of the Egalet Agreement, we transferred the approved New Drug Application, or NDA, for Oxaydo to Egalet and Egalet is granted an exclusive license under our intellectual property rights for development and commercialization of Oxaydo worldwide (the “Territory”) in all strengths, subject to our right to co-promote Oxaydo in the United States. Eaglet launched Oxaydo in the United States late in the third quarter of 2015.

In accordance with the Egalet Agreement, we and Egalet have formed a joint steering committee to coordinate commercialization strategies and the development of product line extensions. Egalet will pay a significant portion of the expenses relating to (i) annual NDA PDUFA product fees, (ii) expenses of the FDA required post-marketing study for Oxaydo and (iii) expenses of clinical studies for product line extensions (additional strengths) of Oxaydo for the United States and will bear all of the expenses of development and regulatory approval of Oxaydo for sale outside the United States. Egalet is responsible for all manufacturing and commercialization activities in the Territory for Oxaydo. Subject to certain exceptions, Egalet will have final decision making authority with respect to all development and commercialization activities for Oxaydo, including pricing, subject to our co-promotion right. Egalet may develop Oxaydo for other countries and in additional strengths, in its discretion.

Egalet paid us an upfront payment of $5 million upon signing of the Egalet Agreement and a $2.5 million milestone on October 9, 2015 in connection with the first commercial sale of Oxaydo. In addition, we will be entitled to a one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year. We will receive from Egalet a stepped royalty at percentage rates ranging from mid-single digits to double-digits on net sales during a calendar year based on Oxaydo net sales during such year (excluding net sales resulting from our co-promotion efforts). In any calendar year in which net sales exceed a specified threshold, we will receive a double digit royalty on all Oxaydo net sales in that year (excluding net sales resulting from our co-promotion efforts). If we exercise our co-promotion rights, we will receive a share of the gross margin attributable to incremental Oxaydo net sales from our co-promotion activities. Egalet’s royalty payment obligations commence on the first commercial sale of Oxaydo and expire, on a country-by-country basis, upon the expiration of the last to expire valid patent claim covering Oxaydo in such country (or if there are no patent claims in such country, then upon the expiration of the last valid claim in the United States or the date when no valid and enforceable listable patent in the FDA’s Orange Book remains with respect to Oxaydo). Royalties will be reduced upon the entry of generic equivalents, as well as for payments required to be made by Egalet to acquire intellectual property rights to commercialize Oxaydo, with an aggregate minimum floor.

The Egalet Agreement expires upon the expiration of Egalet’s royalty payment obligations in all countries. Either party may terminate the Egalet Agreement in its entirety if the other party breaches a payment obligation, or otherwise materially breaches the Egalet Agreement, subject to applicable cure periods, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. We also may terminate the Egalet Agreement with respect to the U.S. and other countries if Egalet materially breaches its commercialization obligations. Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalet’s launch of Oxaydo. Termination does not affect a party’s rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalet’s supply of Oxaydo for a transition period.

Paragraph IV ANDA Litigation and License Grants

On or about September 17, 2012, the FDA began accepting Abbreviated New Drug Applications, or ANDAs, referencing Oxaydo. To date, we have received Paragraph IV Certification Notices under 21 U.S.C. 355(j) (a Paragraph IV Notice) from five separate generic sponsors of an ANDA for a generic drug listing Oxaydo as the reference listed drug. The Paragraph IV Notices state that each generic sponsor believes that our Aversion Technology patents listed in FDA’s Orange Book are invalid, unenforceable or not infringed. We initiated suit against each of Watson Laboratories, Inc. – Florida (Watson), Par Pharmaceutical, Inc., Impax Laboratories, Inc., Sandoz Inc., and Ranbaxy, Inc., each in the United States District Court for the District of Delaware alleging infringement of our U.S. Patent No. 7,510,726 listed in the FDA’s Orange Book.

We dismissed our suit against Watson on the grounds that Watson had amended its ANDA from a Paragraph IV Certification to a Paragraph Certification III, which indicated its intent not to market its generic Oxaydo product in advance of our patent expiry.

We have entered into distinct Settlement Agreements with each of Par, Impax, Ranbaxy and Sandoz to settle our patent infringement actions. Par is the first filer of an ANDA for a generic Oxaydo product and is entitled to the 180-day first filer exclusivity under applicable law and FDA regulations. Par is entitled to launch its generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-bearing license from us that would trigger on January 1, 2022. We currently have Orange Book patents that are due to expire between November 2023 and March 2025. In certain limited circumstances, our license to Par would become effective prior to January 1, 2022. Par is required to pay us royalties in the range of 10% to 15% of Par’s net profits from the sale of its generic Oxaydo product.

Impax and Sandoz are entitled to launch their generic Oxaydo product in the U.S., through the grant of a non-exclusive, royalty-free license from us that would trigger 180 days following the first sale of a generic Oxaydo® product in the U.S. by an entity that is entitled to the 180 day first-filer exclusivity under applicable law and FDA regulations (or if no entity is entitled to such 180 day exclusivity period, the date on which a generic Oxaydo® product is first sold in the U.S. or November 27, 2021, whichever date occurs first). In certain circumstances, our license to Impax and Sandoz would become effective prior to such time. In certain circumstances, Sandoz may be required to pay us a royalty on net profits of their generic Oxaydo product.

Our Settlement Agreement with Ranbaxy provides that Ranbaxy’s current generic of our Oxaydo product that is the subject of its ANDA filing does not infringe our Orange Book listed patents with the FDA. We have not provided Ranbaxy a license to our patents and we may re-commence patent infringement litigation against Ranbaxy if Ranbaxy changes the formulation of its current generic Oxaydo product.

Notwithstanding the settlement of these prior infringement actions, it is possible that other generic manufacturers may also seek to launch a generic version of Oxaydo and challenge our patents. Any determination in such infringement actions that our patents covering our Aversion Technology and Oxaydo are invalid or unenforceable, in whole or in part, or that the products covered by generic sponsors’ ANDAs do not infringe our patents could have a material adverse effect on our operations and financial condition.

Bayer Agreement

On June 15, 2015, we and Bayer entered into a License and Development Agreement ( the “Agreement”) granting Bayer an exclusive worldwide license to our Impede Technology for use in an undisclosed methamphetamine resistant pseudoephedrine –containing product (the “Bayer Licensed Product”) and providing for the joint development of such product utilizing our Impede Technology for the U.S. market. The Agreement also grants Bayer first right to negotiate a license to the Impede technology for certain other products.

We and Bayer have formed a joint development committee to coordinate development of the Bayer Licensed Product. We will be eligible to receive reimbursement of certain of our development costs, success-based development and regulatory milestones payments, and low mid-single digit royalties on net sales of the Bayer Licensed product in countries with patent coverage and a reduced royalty elsewhere.

The term of the Agreement with respect to each country expires when royalties are no longer payable with respect to such country. After expiration of the term Bayer retains a license to sell the Bayer Licensed Product on a royalty free basis. Either party may terminate the Agreement in its entirety if the other party materially breaches the Agreement, subject to an applicable cure period, or in the event the other party makes an assignment for the benefit of creditors, files a petition in bankruptcy or otherwise seeks relief under applicable bankruptcy laws. Bayer may terminate the Agreement immediately prior to completion of our development obligations or at any time upon six (6) months prior written notice thereafter. We may terminate the Agreement with respect to the U.S. if Bayer ceases or suspends development or commercialization of the Bayer Licensed Product for a certain period of time.

Terminated Pfizer Agreement

We had previously entered into a 2007 License, Development and Commercialization Agreement for Oxaydo (named Oxecta™ under a Pfizer trademark) and other Aversion opioid development products with King Pharmaceuticals Research and Development, Inc., which became a subsidiary of Pfizer in 2011 (the “Pfizer Agreement”). By April 2014, we entered into two letter agreements with Pfizer providing for the termination of the Pfizer Agreement and the return of all Aversion product rights to us in exchange for a one-time termination payment of $2.0 million and the purchase certain inventory held by Pfizer. Our termination payment of $2.0 million has been recorded on our financial statements as an intangible asset and is being amortized over the remaining useful life of the patent for Aversion Oxycodone. We also purchased from Pfizer selected raw and packaging material inventories for $260 thousand relating to Oxaydo. During the first quarter of 2015, we recorded a 100% reserve against these inventories which is reflected in operating expenses and we wrote off the inventories against the reserve during both the second and third quarters 2015.

Purdue Pharma

The Company received a $250 thousand payment from Purdue Pharma L.P. in June 2015 relating to a December 2014 agreement to settle a patent interference action on U.S. Patent No. 8,101,630 issued to Acura.

REVENUE RECOGNITION

9 Months Ended

Sep. 30, 2015

Revenue Recognition [Abstract]

REVENUE RECOGNITION

NOTE 4 - REVENUE RECOGNITION

Revenue is generally realized or realizable and earned when there is persuasive evidence an arrangement exists, delivery has occurred or services rendered, the price is fixed and determinable, and collection is reasonably assured. In connection with our license, development and commercialization agreements, we can recognize milestone revenue, collaboration revenue and royalty revenue.

Milestone Revenue

Milestone revenue is contingent upon the achievement of certain pre-defined events in the development agreements. Milestone payments are recognized as revenue upon achievement of the “at risk” milestone events, which represent the culmination of the earnings process related to that milestone. Milestone payments are triggered either by the results of our research and development efforts or by events external to us, such as regulatory approval to market a product. As such, the milestones are substantially at risk at the inception of an agreement, and the amounts of the payments assigned thereto are commensurate with the milestone achieved. In addition, upon the achievement of a milestone event, we have no future performance obligations related to that milestone payment. Each milestone payment is non-refundable and non-creditable when made. In October 2015, Egalet paid us a $2.5 million milestone payment connection with the first commercial sale of Oxaydo.

Collaboration Revenue

Collaboration revenue is derived from reimbursement of development expenses and are recognized when costs are incurred pursuant to the agreement. The ongoing research and development services being provided under the collaboration are priced at fair value based upon the reimbursement of expenses incurred pursuant to the collaboration agreement. We recognized $95 thousand of collaboration revenue during the third quarter of 2015.

Royalties from Pfizer

Commencing in February 2013, we began earning royalties based on net sales of Aversion Oxycodone by Pfizer. We earned royalties of approximately $4 thousand for the nine months ended September 30, 2014. The Pfizer Agreement was terminated effective April 9, 2014 and Pfizer’s royalty payment obligations ceased as of such date.

Product Sales

We record revenue from our Nexafed product sales when the price is fixed and determinable at the date of sale, title and risk of ownership have been transferred to the customer, and returns can be reasonably estimated.

Nexafed was launched in mid-December 2012 and Nexafed Sinus Pressure + Pain was launched in February 2015. We sell our Nexafed products in the United States to wholesale pharmaceutical distributors as well as directly to chain drug stores. Our Nexafed products are sold subject to the right of return usually for a period of up to twelve months after the product expiration. The Nexafed products currently have a shelf life of twenty-four months from the date of manufacture. Given the limited sales history of our Nexafed products, we could not reliably estimate expected returns of the product at the time of shipment to certain customers and accordingly we had deferred revenue. During the first quarter of 2015 we determined we had obtained sufficient sales returns history to reasonably estimate future returns from those customers. As a result of this change, we recorded a one-time adjustment in the first quarter of 2015 to recognize revenue that had previously been deferred, resulting in additional net revenues of $314 thousand after recording an allowance for sales returns of $120 thousand, and cost of sales of $255 thousand. At September 30, 2015, we have a $173 thousand sales returns liability which will be reviewed against sales returns activity each quarter. Revenue is being recognized at the time the products are sold to a customer.

Shipping and Handling Costs

We record our shipping and handling costs in selling expenses. The amounts recorded to selling expenses from the shipments of Nexafed products during each of the nine month periods ended September 30, 2015 and 2014 were not material.

RESEARCH AND DEVELOPMENT ACTIVITIES

9 Months Ended

Sep. 30, 2015

Research and Development [Abstract]

RESEARCH AND DEVELOPMENT ACTIVITIES

NOTE 5 - RESEARCH AND DEVELOPMENT ACTIVITIES

Research and Development (“R&D”) expenses include internal R&D activities, external Contract Research Organization (“CRO”) services and their clinical research sites, and other activities. Internal R&D activity expenses include facility overhead, equipment and facility maintenance and repairs, laboratory supplies, pre-clinical laboratory experiments, depreciation, salaries, benefits, and share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting, and regulatory legal counsel. Internal R&D activities and other activity expenses are charged to operations as incurred. We make payments to the CRO's based on agreed upon terms and may include payments in advance of a study starting date. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the stage of completion of a study as provided by the CRO. Accrued CRO costs are subject to revisions as such studies progress to completion. Revisions are charged to expense in the period in which the facts that give rise to the revision become known. We did not have any accrued CRO costs and clinical trial study expenses at either September 30, 2015 or December 31, 2014. We did not have any prepaid CRO costs and clinical trial study expenses at either September 30, 2015 or December 31, 2014.

- Definition

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

+ References+ Details

INVESTMENTS IN MARKETABLE SECURITIES

9 Months Ended

Sep. 30, 2015

Investments, Debt and Equity Securities [Abstract]

INVESTMENTS IN MARKETABLE SECURITIES

NOTE 6 - INVESTMENTS IN MARKETABLE SECURITIES

Investments in marketable securities consisted of the following (in millions):

	September 30,		December 31,
	2015		2014
Marketable securities:
Corporate bonds - maturing within 1 year	$	3.6	$	3.5
Corporate bonds - maturing after 1 year and through March 2017		1.0		2.8
Exchange-traded funds		7.3		5.0
Total marketable securities	$	11.9	$	11.3

The Company’s marketable securities are classified as available-for-sale and are recorded at fair value based on quoted market prices or net asset value using the specific identification method. The purchase cost of corporate bonds may include a purchase price premium or discount which will be amortized or accreted against earned interest income to the maturity date of the bond. Our investments are classified as current in the Company’s Consolidated Balance Sheets as they may be sold within one year in response to changes in market prices or interest rates, to realign our investment concentrations or to meet our working capital needs.

The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions):

	September 30, 2015
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
Available-for-sale:
Corporate bonds	$	4.6	$	-	$	-	$	4.6
Exchange-traded funds		7.3		-		-		7.3
Total – Current	$	11.9	$	-	$	-	$	11.9

	December 31, 2014
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
Available-for-sale:
Corporate bonds	$	6.3	$	-	$	-	$	6.3
Exchange-traded funds		5.0		-		-		5.0
Total - Current	$	11.3	$	-	$	-	$	11.3

Fair Value Measurement

Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. A financial asset or liability’s classification within the above hierarchy is determined based on the lowest level input that is significant to the fair value measurement.

Our assets measured at fair value or disclosed at fair value on a recurring basis as at September 30, 2015 and December 31, 2014 consisted of the following (in millions):

	September 30, 2015
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds	$	4.6	$	-	$	4.6	$	-
Exchange-traded funds		7.3		7.3		-		-
Total	$	11.9	$	7.3	$	4.6	$	-

	December 31, 2014
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds	$	6.3	$	-	$	6.3	$	-
Exchange-traded funds		5.0		5.0		-		-
Total	$	11.3	$	5.0	$	6.3	$	-

Accumulated Other Comprehensive Income (Loss)

Unrealized gains or losses on marketable securities are recorded in accumulated other comprehensive income (loss). Accumulated other comprehensive income (loss) at September 30, 2015 and December 31, 2014 consisted of unrealized losses on securities of $11 thousand and $13 thousand, respectively.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Debt Security

-URI http://asc.fasb.org/extlink&oid=6509901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 320

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-Glossary Equity Security

-URI http://asc.fasb.org/extlink&oid=6511694

+ Details

INVENTORIES

9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

INVENTORIES

NOTE 7 – INVENTORIES

Inventories may consist of both raw and packaging materials on our Oxaydo product and finished goods held for distribution and sale on our Nexafed products. During 2014, we purchased raw and packaging material inventories for $260 thousand from Pfizer on the Oxaydo product we reacquired from them. Inventories are stated at the lower of cost (first-in, first-out method) or market (net realizable value). We write down inventories to net realizable value based on forecasted demand and market conditions, which may differ from actual results. During the first quarter of 2015, we recorded a $260 thousand reserve against the raw and packaging material inventory on our Oxaydo product as Egalet secured its own material requirements. During the three and nine months ended September 30, 2015, we wrote off $126 thousand and $260 thousand of inventories against the reserve, respectively. During the three and nine months ended September 30, 2015 we recorded finished good inventory reserves of $27 thousand and $74 thousand, respectively. During the three and nine months ended September 30, 2014, we recorded finished good inventory reserves of $0 and $201 thousand, respectively.

We had recorded Nexafed deferred revenue of $0.35 million at December 31, 2014. The related cost of sales of $0.22 million at December 31, 2014 is reported in our balance sheet in the other current deferred assets account and excluded from the reported year end inventories. We recognize both the revenue and cost of sales on these Nexafed shipments once the right of return no longer exists or adequate history and information becomes available to estimate sales returns. During the first quarter of 2015, we determined we had obtained sufficient sales returns history to reasonably estimate future returns.

Our purchases of ingredients and other materials required in our development and clinical trial activities are expensed as incurred.

Inventories are summarized as follows (in thousands):

	September 30,		December 31,
	2015		2014
Raw and packaging materials	$	-	$	260
Finished goods		148		44
Total		148		304
Less: reserve for finished goods		(74)		(-)
Net	$	74	$	304

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

PROPERTY, PLANT AND EQUIPMENT

9 Months Ended

Sep. 30, 2015

Property, Plant and Equipment [Abstract]

PROPERTY, PLANT AND EQUIPMENT

NOTE 8 – PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are stated at cost, less accumulated depreciation of $1.84 million and $1.79 million at September 30, 2015 and December 31, 2014, respectively. We have no leasehold improvements. Betterments are capitalized and maintenance and repairs are charged to operations as incurred. When a depreciable asset is retired from service, the cost and accumulated depreciation is removed from the respective accounts.

Our depreciation expense was $92 thousand and $90 thousand for the nine months ended September 30, 2015 and 2014, respectively. Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are:

Building and improvements		10 - 40 years
Land and improvements		20 - 40 years
Machinery and equipment		7 - 10 years
Scientific equipment		5 - 10 years
Computer hardware and software		3 - 10 years

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

ACCRUED EXPENSES

9 Months Ended

Sep. 30, 2015

Payables and Accruals [Abstract]

ACCRUED EXPENSES

NOTE 9 - ACCRUED EXPENSES

Accrued expenses are summarized as follows (in thousands):

	September 30,		December 31,
	2015		2014
Payroll, payroll taxes, and benefits	$	260	$	94
Professional services		269		253
Franchise taxes		10		13
Property taxes		13		15
Marketing and promotion		120		61
Non-clinical and regulatory services		57		83
Other fees and services		96		49
Total	$	825	$	568

DEBT

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

DEBT

NOTE 10 – DEBT

On December 27, 2013, we entered into a Loan and Security Agreement (the “Loan Agreement”) with Oxford Finance LLC (“Oxford” or the “Lender”), for a term loan to the Company in the principal amount of $10.0 million (the “Term Loan”). The full principal amount of the Term Loan was funded on December 27, 2013. We are using the proceeds of the Loan Agreement for general working capital and to fund our business requirements. The Term Loan accrues interest at a fixed rate of 8.35% per annum (with a default rate of 13.35% per annum). The Company was required to make monthly interest-only payments until the April 1, 2015 (“Amortization Date”) and on the Amortization Date, the Company began to make payments of principal and accrued interest in equal monthly installments of $260 thousand sufficient to amortize the Term Loan through the maturity date of December 1, 2018. All unpaid principal and accrued and unpaid interest with respect to the Term Loan is due and payable in full on December 1, 2018. As of October 30, 2015 we have made $1.36 million in principal payments. As security for its obligations under the Loan Agreement, the Company granted Lender a security interest in substantially all of its existing and after-acquired assets, exclusive of its intellectual property assets. Pursuant to the Loan Agreement, the Company is not allowed to pledge its intellectual property assets to others. Upon the execution of the Loan Agreement, we issued to the Lender warrants to purchase an aggregate of up to 60 thousand shares of our common stock at an exercise price equal to $8.00 per share (after adjustment for our one-for-five reverse stock split) (the “Warrants”). We recorded $400 thousand as debt discount associated with the fair value of the Warrants and are amortizing it to interest expense over the term of the loan using the loan’s effective interest rate. The Warrants are immediately exercisable for cash or by net exercise and will expire December 27, 2020.

On January 7, 2015, we and Oxford entered into an amendment to the Loan Agreement. Pursuant to the amendment, (i) the exercise price of the Warrants was lowered from $8.00 to $2.52 per share (the average closing price of our common stock on Nasdaq for the 10 trading days preceding the date of the amendment and after giving effect to our one-for-five reverse stock split) and we recorded additional debt discount of $33 representing the fair value of the warrant modification, (ii) we agreed to maintain a $2.5 million cash reserve until such time as we have repaid $5.0 million in principal of the Term Loan, and (iii) the Lender consented to the terms of our Collaboration and License Agreement with Egalet relating to our Oxaydo product.

The Company may voluntarily prepay the Term Loan in full, but not in part, and any prepayment is subject to a prepayment premium equal to 2% of the principal prepaid, if prepaid prior to December 27, 2015, and 1% of the principal prepaid if prepaid after December 27, 2015. In addition, at the maturity, termination or upon voluntary or mandatory prepayment of the Term Loan the Company must pay the Lender an additional one-time interest payment of $795 thousand. We will incur and accrue additional monthly interest expense over the term of the loan for this additional one-time interest payment using the loan’s effective cash interest rate.

The Company was obligated to pay customary lender fees and expenses, including a one-time facility fee of $50 thousand and the Lender’s expenses in connection with the Loan Agreement. Combined with the Company’s own expenses and a $100 thousand consulting placement fee, the Company incurred $231 thousand in deferred debt issue costs. We are amortizing these costs, including debt modification additional costs, into interest expense over the term of the loan using the loan’s effective interest rate of 10.16%.

The Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, limits or restrictions on the Company’s ability to incur liens, incur indebtedness, pay dividends, redeem stock, and merge or consolidate and dispose of assets. In addition, it contains customary events of default that entitles the Lender to cause any or all of the Company’s indebtedness under the Loan Agreement to become immediately due and payable. The events of default (some of which are subject to applicable grace or cure periods), include, among other things, non-payment defaults, covenant defaults, a material adverse change in the Company, bankruptcy and insolvency defaults and material judgment defaults.

Our debt at September 30, 2015 is summarized below (in thousands):

Debt	Current		Long-term		Total
Balance at Dec 31, 2014	$	1,758	$	8,242	$	10,000
Principal payments		(1,160)		-		(1,160)
Classification		1,872		(1,872)		-
Balance at Sept 30, 2015	$	2,470	$	6,370	$	8,840

Debt Discount	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(281)	$	(281)
Modification of warrants		-		(33)		(33)
Amortization expense		-		94		94
Balance at Sept 30, 2015	$	-	$	(220)	$	(220)

Debt Issuance Costs	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(162)	$	(162)
Additions		-		-		-
Amortization expense		-		50		50
Balance at Sept 30, 2015	$	-	$	(112)	$	(112)

Net Debt at Sept 30, 2015	$	2,470	$	6,038	$	8,508

Our interest expense during each of the three and nine months ended September 30, 2015 and 2014 consisted of the following (in thousands):

	Three months Ended				Nine months Ended
	September 30,				September 30,
	2015		2014		2015		2014
Interest expense:
Term loan	$	236	$	257	$	748	$	767
Debt discount		31		30		94		89
Debt issue costs		16		17		50		51
Total interest expense	$	283	$	304	$	892	$	907

Our remaining principal payments on the debt as of September 30, 2015 is as follows (in thousands):

Calendar	Principal
Year	Payment
2015	$	598
2016		2,522
2017		2,741
2018		2,979
Total	$	8,840

EQUITY FINANCING

9 Months Ended

Sep. 30, 2015

Equity [Abstract]

EQUITY FINANCING

NOTE 11 – EQUITY FINANCING

Our universal shelf registration statement on Form S-3 was declared effective by the Securities and Exchange Commission (“SEC”) on March 15, 2013. On April 18, 2013, we filed a prospectus supplement with the SEC pursuant to which we may sell shares of our common stock from time to time in “at the market” offerings and certain other transactions, having sales proceeds of up to $13 million. We did not sell any shares of our common stock pursuant to our prospectus supplement during the nine months ended September 30, 2014. During the nine months ended September 30, 2015, we sold approximately 54 thousand shares of our common stock (after giving effect to our one-for-five reverse stock split) for gross proceeds of $225 thousand. Transaction costs were approximately $8 thousand. The net proceeds of $217 thousand were used for general corporate purposes. In order to allow for the sale of our shares of common stock under our shelf registration statement pursuant to the Placement Agency Agreement and Securities Purchase Agreement described below, on June 30, 2015, we and MLV & Co., LLC, as sales agent, terminated the At Market Issuance Sales Agreement dated April 18, 2013, thereby terminating any further “at the market offerings” under our prospectus supplement filed with the SEC on April 18, 2013.

On June 30, 2015, we entered into a Placement Agency Agreement (the “Placement Agency Agreement”) with Roth Capital Partners, LLC (“Roth”), pursuant to which we engaged Roth to act as sole placement agent in a registered direct offering (the “Offering”) of 1.958 million shares of our common stock, par value $.01 (after giving effect to our one-for-five reverse stock split). On June 30, 2015, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional investors (the “Purchasers”), pursuant to which we agreed to sell 1.958 million shares of our common stock at a price of $3.90 per share (after giving effect to our one-for-five reverse stock split) to the Purchasers in the Offering, for gross proceeds to the Company of $7.63 million, before expenses. The Offering was made pursuant to a prospectus supplement dated June 30, 2015 filed with the Securities and Exchange Commission in connection with a takedown from the Company’s shelf registration statement on Form S-3 (File No. 333-187075), which became effective on March 15, 2013, and the related base prospectus included in the Registration Statement, as supplemented by the prospectus supplement. The transactions contemplated by the Placement Agency Agreement and the Purchase Agreement closed on July 7, 2015.

Pursuant to the terms of the Placement Agency Agreement, we paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering and reimbursed Roth $35 thousand for its expenses. The net proceeds from the Offering, after these and other legal expenses, was $7.0 million.

COMMON STOCK WARRANTS

9 Months Ended

Sep. 30, 2015

Stockholders Equity Note [Abstract]

COMMON STOCK WARRANTS

NOTE 12 - COMMON STOCK WARRANTS

We have outstanding common stock purchase warrants (“warrants”) exercisable for 60 thousand shares of our common stock having an exercise price of $2.52 per share (after giving effect to our one-for-five reverse stock split) with an expiration date in December 2020. See Note 10 for a discussion of the reduction of the exercise price of the warrants to $2.52 per share. These warrants contain a cashless exercise feature. Our common stock warrant activity during the nine months ended September 30, 2015 and 2014 is shown below:

	Nine months Ended
	September 30,
	2015				2014
			Weighted				Weighted
			Average				Average
	Number		Exercise		Number		Exercise
	(000’s)		Price		(000’s)		Price
Outstanding, beginning		60	$	8.00		431	$	15.75
Issued		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		(371)		17.00
Outstanding, ending		60	$	2.52		60	$	8.00

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

+ Details

SHARE-BASED COMPENSATION

9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

SHARE-BASED COMPENSATION

NOTE 13 - SHARE-BASED COMPENSATION

Share-based Compensation

We have three share-based compensation plans covering stock options and RSUs for our employees and directors.

We measure our compensation cost related to share-based payment transactions based on fair value of the equity or liability instrument issued. For purposes of estimating the fair value of each stock option unit on the date of grant, we utilize the Black-Scholes option-pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected volatility factor of the market price of our common stock (as determined by reviewing our historical public market closing prices). Our accounting for share-based compensation for RSUs is based on the fair-value method. The fair value of the RSUs is the market price of our common stock on the date of grant, less its exercise cost.

Our share-based compensation expense recognized in the Company’s results of operations comprised the following (in thousands):

	Three months Ended				Nine months Ended
	September 30,				September 30,
	2015		2014		2015		2014
Research and development expense:
Stock options	$	39	$	57	$	117	$	170

General and administrative expense:
Stock options	$	107	$	141	$	293	$	423
Restricted stock units		4		31		51		123
Subtotal	$	111	$	172	$	344	$	546

Total	$	150	$	229	$	461	$	716

Stock Option Award Plans

We have one stock option plan in effect, and one stock option plan has expired by its terms, but pursuant to which stock options have been granted and remain outstanding. Our stock option award activity during the nine months ended September 30, 2015 and 2014 is shown below:

	Nine months Ended
	September 30,
	2015				2014
	Number		Weighted				Weighted
	of		Average		Number of		Average
	Options		Exercise		Options		Exercise
	(000’s)		Price		(000’s)		Price
Outstanding, beginning		911	$	20.7		747	$	24.95
Granted		-		-		-		-
Exercised		-		-		(6)		6.50
Forfeited or expired		(16)		24.50		(6)		18.00
Outstanding, ending		895	$	20.66		735	$	25.15
Options exercisable		779	$	23.21		674	$	26.65

No stock options were exercised during the nine months ended September 30, 2015. During the nine months ended September 30, 2014, a total of 6 thousand stock options were exercised by our employees. Of the total amount of these stock option exercises, 5 thousand of stock options were exercised under various cashless exercise features of the plan. Our employees elected to have 4 thousand shares withheld in satisfaction of $36 thousand for both the exercise costs and withholding tax obligations on those options, resulting in the net issuance of 3 thousand shares of common stock from all stock option exercises.

Restricted Stock Unit Award Plans

We have two Restricted Stock Unit Award Plans for our employees and non-employee directors, a 2005 Restricted Stock Unit Award Plan (the “2005 RSU Plan”) and a 2014 Restricted Stock Unit Award Plan (the “2014 RSU Plan”). Vesting of an RSU entitles the holder to receive a share of our common stock on a distribution date. The share-based compensation cost to be incurred on a granted RSU is the RSU’s fair value, which is the market price of our common stock on the date of grant, less its exercise cost. The compensation cost is amortized to expense over the vesting period of the RSU award.

A summary of the grants under the RSU Plans consisted of the following (in thousands):

	Nine months Ended September 30,
	2015				2014
			Number of				Number of
	Number		Vested		Number		Vested
	of RSUs		RSUs		of RSUs		RSUs
Outstanding, beginning		29		29		166		166
Granted		42		-		29		-
Distributed		(26)		(26)		(166)		(166)
Vested		-		32		-		22
Forfeited or expired		-		-		-		-
Outstanding, ending		45		35		29		22

2005 Restricted Stock Unit Award Plan

Under our 2005 RSU Plan, one-fourth of vested shares of common stock underlying RSU awards of 0.66 million shares were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of years 2011 thru 2014. On January 1, 2014, 100 thousand shares were distributed to the holders while 66 thousand shares were withheld by the Company upon elections made to exchange RSUs in satisfaction of $0.5 million withholding tax obligations.

All RSUs granted under the 2005 RSU Plan had been distributed effective January 1, 2014.

2014 Restricted Stock Unit Award Plan

Our 2014 RSU Plan was approved by shareholders on May 1, 2014 and permits the grant of up to 400 thousand shares of our common stock pursuant to awards under the 2014 RSU Plan. As of September 30, 2015, 330 thousand shares are available for award under the 2014 RSU Plan.

Information about the awards under the 2014 RSU Plan is as follows:

⋅

On May 1, 2014, we awarded approximately 7 thousand RSUs to each of our 4 non-employee directors. Such RSU awards vested 50% on June 30, 2014 and 25% on each of September 30 and December 31, 2014. Such non-employee director awards allow for non-employee directors to receive payment in cash, instead of stock, for up to 40% of each RSU award. The RSU awards subject to cash settlement are recorded as a liability in the Company’s balance sheet. The liability was $26 thousand at December 31, 2014. Accordingly the vested portion of the awards containing the cash settlement feature are being marked-to-market each reporting period until they are distributed. Marked-to-market accounting can create fluctuations in our compensation expense including the need to record additional expense. RSU awards are generally distributed on the first business day of the year after vesting, but such distribution can be deferred until a later date at the election of the non-employee director.

⋅

On January 2, 2015, we awarded approximately 10 thousand RSUs to each of our 4 non-employee directors which also allow for them to receive payment in cash, instead of stock, for up to 40% of each RSU award. Such awards vest 25% at the end of each calendar quarter in 2015. The RSU awards subject to cash settlement are subject to marked-to market accounting and the liability recorded in the Company’s balance sheet was $33 thousand at September 30, 2015. Distributions of stock under the January 2, 2015 award cannot be deferred until a later date and the stock under such awards will be distributed on January 4, 2016.

Information about the distribution of shares under the 2014 RSU Plan is as follows:

⋅

On January 2, 2015, 26 thousand RSUs from the May 1, 2014 award were distributed and 4 thousand RSUs were deferred until a future distribution date. Of the 26 thousand RSUs distributed, 20 thousand RSUs were distributed in common stock and 6 thousand RSUs were settled in cash.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

INCOME TAXES

9 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 14 – INCOME TAXES

We account for income taxes under the liability method. Under this method, deferred income tax assets and liabilities are determined based on differences between financial reporting and income tax basis of assets and liabilities and are accounted for using the enacted income tax rates and laws that will be in effect when the differences are expected to reverse. Additionally, net operating loss and tax credit carryforwards are reported as deferred income tax assets. The realization of deferred income tax assets is dependent upon future earnings. A valuation allowance is required against deferred income tax assets if, based on the weight of available evidence, it is more likely than not that some or all of the deferred income tax assets may not be realized. At both September 30, 2015 and December 31, 2014, all our remaining net deferred income tax assets were offset by a valuation allowance due to uncertainties with respect to future utilization of net operating loss (“NOL”) carryforwards. If in the future it is determined that additional amounts of our deferred income tax assets would likely be realized, the valuation allowance would be reduced in the period in which such determination is made and an additional benefit from income taxes in such period would be recognized. We have approximately $51.5 million federal income tax benefits at December 31, 2014 derived from $151.4 million Federal NOLs at the U.S. statutory tax rate of 34% and $2.9 million state NOLs, available to offset future taxable income, some of which have limitations for use as prescribed under IRC Section 382. Our Federal and state NOLs will expire in varying amounts between 2016 and 2034 if not used, and those expirations will cause fluctuations in our valuation allowances. As of December 31, 2014 we had federal research and development tax credits of approximately $1.1 million, which expire for the tax years 2024 through 2034. We also had approximately $0.3 million of Indiana state research and development tax credits, which expire for the tax years 2015 through 2017.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

EARNINGS PER SHARE ("EPS")

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

EARNINGS PER SHARE ("EPS")

NOTE 15 – EARNINGS PER SHARE (“EPS”)

Basic EPS is computed by dividing net income or loss by the weighted average common shares outstanding during a period, including shares weighted related to vested Restricted Stock Units (“RSUs”) (see Note 13). Diluted EPS is based on the treasury stock method and computed based on the same number of shares used in the basic share calculation and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and stock warrants, assuming the exercise of all in-the-money stock options and warrants. Common stock equivalents are excluded from the computation where their inclusion would be anti-dilutive. No such adjustments were made for 2015 and 2014 as the Company reported a net loss for the three and nine month periods, and including the effects of common stock equivalents in the diluted EPS calculation would have been antidilutive.

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share amounts):

	Three months Ended				Nine months Ended
	September 30,				September 30,
	2015		2014		2015		2014
EPS – basic and diluted
Numerator: net loss	$	(2,649)	$	(2,904)	$	(4,073)	$	(10,513)
Denominator:
Common shares		11,653		9,770		10,432		9,769
Vested RSUs		24		14		14		5
Basic and diluted weighted average shares outstanding		11,677		9,784		10,446		9,774
EPS – basic and diluted	$	(0.23)	$	(0.30)	$	(0.39)	$	(1.08)

Excluded securities:
Common shares issuable:
Stock options		895		735		895		735
Nonvested RSUs		10		7		10		7
Common stock warrants		60		60		60		60
Total excluded common shares		965		802		965		802

- Definition

The entire disclosure for earnings per share.

+ References+ Details

COMMITMENTS AND CONTINGENCIES

9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 16 – COMMITMENTS AND CONTINGENCIES

Purdue Pharma Complaint

In April 2015, Purdue Pharma L.P., Purdue Pharmaceuticals L.P. and The P.F. Laboratories, Inc. (collectively, “Purdue”) commenced a patent infringement lawsuit against us and our Oxaydo™ product licensee Egalet US, Inc. and its parent Egalet Corporation in the United States District Court for the District of Delaware alleging our Oxaydo product infringes Purdue’s U.S. Patent No. 8,389,007 (the “’007 patent”). The complaint seeks injunctive relief as well as awards of damages and attorneys’ fees. We deny the allegations in the complaint, believe they are without merit and are defending the action vigorously. As is the case with patent litigation, there is a risk that the Court may enjoin the making, using, selling and offering for sale Oxaydo and/or may find that Oxaydo infringes the ‘007 patent. As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of September 30, 2015.

Reglan®/Metoclopramide Litigation

Halsey Drug Company, as predecessor to us, has been named along with numerous other companies as a defendant in cases filed in three separate state coordinated litigations pending in Pennsylvania, New Jersey and California, respectively captioned In re: Reglan®/Metoclopramide Mass Tort Litigation, Philadelphia County Court of Common Pleas, January Term, 2010, No. 01997; In re: Reglan Litigation, Superior Court of New Jersey, Law Division, Atlantic County, Case No. 289, Master Docket No. ATL-L-3865-10; and Reglan/Metoclopramide Cases, Superior Court of California, San Francisco County, Judicial Council Coordination Proceeding No. 4631, Superior Court No.: CJC-10-004631. In addition, Acura was served with a similar complaint by two individual plaintiffs in Nebraska federal court, which plaintiffs voluntarily dismissed in December 2014. In this product liability litigation against numerous pharmaceutical product manufacturers and distributors, including Acura, plaintiffs claim injuries from their use of the Reglan brand of metoclopramide and generic metoclopramide.

In the Pennsylvania action, over 200 lawsuits have been filed against Acura and Halsey Drug Company alleging that plaintiffs developed neurological disorders as a result of their use of the Reglan brand and/or generic metoclopramide. In the New Jersey action, plaintiffs filed approximately 150 lawsuits against us, but served less than 50 individual lawsuits upon us. In the California action, there are 89 pending cases against us, with more than 445 individual plaintiffs.

In the lawsuits filed to date, plaintiffs have not confirmed they ingested any of the generic metoclopramide manufactured by Acura. We discontinued manufacture and distribution of generic metoclopramide more than 18 years ago. In addition, we believe the June 23, 2011 decision by the U.S. Supreme Court in PLIVA v. Mensing (“Mensing decision”) holding that state tort law failure to warn claims against generic drug companies are pre-empted by the 1984 Hatch-Waxman Act Amendments and federal drug regulations will assist us in favorably resolving these cases.

In New Jersey, Generic Defendants, including Acura, filed dispositive motions based on the Mensing decision, which the Court granted with a limited exception. In June 2012, the New Jersey trial court dismissed all of the New Jersey cases pending against Acura with prejudice. It is possible that this ruling may eventually be appealed by plaintiffs at the conclusion of the litigation in the trial court.

In Pennsylvania, and California, Generic Defendants, including Acura, also filed dispositive motions based on the Mensing decision.

In Pennsylvania, on November 18, 2011, the trial court denied Generic Defendants’ dispositive preemption motions, without prejudice. In July 2013, the Pennsylvania Superior Court issued an adverse decision, and a subsequent appeal to the Pennsylvania Supreme Court was denied. On December 16, 2014, the Generic Defendants filed a Joint Petition for Certiorari with the United States Supreme Court captioned Teva Pharmaceuticals USA, Inc. et al. v. Dorothy Bentley, et al., No. 14-711 (U.S.) seeking reversal of the Pennsylvania state court decision. On April 27, 2015, the U.S. Supreme Court denied this Petition and this matter has been returned to the trial court for further proceedings. Pending a further court order, these proceedings are stayed. On July 16, 2015, the court began to resume preliminary procedural steps to narrow this litigation before lifting the stay including requests for plaintiffs to voluntarily discontinue cases, such as those filed against Acura, where there is no case-specific product identification. To the extent, however, that plaintiffs intend to pursue these claims, Acura nonetheless remains optimistic that most, if not all, of these Philadelphia cases will eventually be dismissed against it based upon the favorable aspects of the Superior Court’s narrow preemption ruling and lack of product identification, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by Acura’s insurance carrier.

In California, the trial court entered a May 25, 2012 Order denying Generic Defendants’ dispositive preemption motions. The Generic Defendants’ appeals from this order were denied by the California appellate courts. In May 2014, the California Court denied a subsequent demurrer and motion to strike seeking dismissal of plaintiffs’ manufacturing defect and defective product claims to the extent that they are barred by federal preemption based upon the June 2013 Bartlett decision. Thus far, Acura and most Generic Defendants have not been required to file answers or other responsive pleadings in each individual case in which they are named defendants. However, the individual cases against Acura have been stayed pending resolution of certain jurisdictional issues relating to cases filed by non-resident California plaintiffs and further action by the trial court. Subject to further developments, plaintiffs may be permitted to proceed with these lawsuits against Acura including state law claims based on (1) failing to communicate warnings to physicians through “Dear Doctor” letters; and (2) failure to update labeling to adopt brand labeling changes. The California trial court also has acknowledged the preemptive effect of Mensing so that any claim “that would render the generic defendants in violation of federal law if they are found responsible under a state law cause of action, would not be permissible.” To date, however, none of these plaintiffs have confirmed they ingested any of the generic metoclopramide manufactured by Acura. Therefore, we expect the number of plaintiffs with possible claims to be reduced voluntarily or by motion practice. Action will be taken in an effort to dismiss Acura from these cases, although there can be no assurance in this regard. Legal fees related to this matter are currently covered by our insurance carrier.

As any potential loss is neither probable nor estimable, we have not accrued for any potential loss related to these matters as of September 30, 2015 and we are presently unable to determine if any potential loss would be covered by our insurance carrier.

Facility Lease

The Company leases administrative office space in Palatine, Illinois under a lease expiring March 31, 2016 for approximately $25 thousand annually.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

INVESTMENTS IN MARKETABLE SECURITIES (Tables)

9 Months Ended

Sep. 30, 2015

Investments, Debt and Equity Securities [Abstract]

Marketable securities

Investments in marketable securities consisted of the following (in millions):

	September 30,		December 31,
	2015		2014
Marketable securities:
Corporate bonds - maturing within 1 year	$	3.6	$	3.5
Corporate bonds - maturing after 1 year and through March 2017		1.0		2.8
Exchange-traded funds		7.3		5.0
Total marketable securities	$	11.9	$	11.3

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value

The following tables provide a summary of the fair value and unrealized gains (losses) related to the Company’s available-for-sale securities (in millions):

	September 30, 2015
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
Available-for-sale:
Corporate bonds	$	4.6	$	-	$	-	$	4.6
Exchange-traded funds		7.3		-		-		7.3
Total – Current	$	11.9	$	-	$	-	$	11.9

	December 31, 2014
			Gross		Gross
			Unrealized		Unrealized		Fair
	Cost		Gains		Losses		Value
Available-for-sale:
Corporate bonds	$	6.3	$	-	$	-	$	6.3
Exchange-traded funds		5.0		-		-		5.0
Total - Current	$	11.3	$	-	$	-	$	11.3

Fair Value, Assets Measured on Recurring Basis

Our assets measured at fair value or disclosed at fair value on a recurring basis as at September 30, 2015 and December 31, 2014 consisted of the following (in millions):

	September 30, 2015
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds	$	4.6	$	-	$	4.6	$	-
Exchange-traded funds		7.3		7.3		-		-
Total	$	11.9	$	7.3	$	4.6	$	-

	December 31, 2014
	Total		Level 1		Level 2		Level 3
Assets:
Corporate bonds	$	6.3	$	-	$	6.3	$	-
Exchange-traded funds		5.0		5.0		-		-
Total	$	11.3	$	5.0	$	6.3	$	-

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References+ Details

INVENTORIES (Tables)

9 Months Ended

Sep. 30, 2015

Inventory Disclosure [Abstract]

INVENTORIES

Inventories are summarized as follows (in thousands):

	September 30,		December 31,
	2015		2014
Raw and packaging materials	$	-	$	260
Finished goods		148		44
Total		148		304
Less: reserve for finished goods		(74)		(-)
Net	$	74	$	304

PROPERTY, PLANT AND EQUIPMENT (Tables)

9 Months Ended

Sep. 30, 2015

Property, Plant and Equipment [Abstract]

Property Plant and Equipment

Depreciation expense is recorded on a straight-line basis over the estimated useful lives of the related assets. The estimated useful lives of the major classification of depreciable assets are:

Building and improvements		10 - 40 years
Land and improvements		20 - 40 years
Machinery and equipment		7 - 10 years
Scientific equipment		5 - 10 years
Computer hardware and software		3 - 10 years

DEBT (Tables)

9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Schedule of Debt

Our debt at September 30, 2015 is summarized below (in thousands):

Debt	Current		Long-term		Total
Balance at Dec 31, 2014	$	1,758	$	8,242	$	10,000
Principal payments		(1,160)		-		(1,160)
Classification		1,872		(1,872)		-
Balance at Sept 30, 2015	$	2,470	$	6,370	$	8,840

Debt Discount	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(281)	$	(281)
Modification of warrants		-		(33)		(33)
Amortization expense		-		94		94
Balance at Sept 30, 2015	$	-	$	(220)	$	(220)

Debt Issuance Costs	Current		Long-term		Total
Balance at Dec 31, 2014	$	-	$	(162)	$	(162)
Additions		-		-		-
Amortization expense		-		50		50
Balance at Sept 30, 2015	$	-	$	(112)	$	(112)

Net Debt at Sept 30, 2015	$	2,470	$	6,038	$	8,508

Schedule of Interest Expense

Our interest expense during each of the three and nine months ended September 30, 2015 and 2014 consisted of the following (in thousands):

	Three months Ended				Nine months Ended
	September 30,				September 30,
	2015		2014		2015		2014
Interest expense:
Term loan	$	236	$	257	$	748	$	767
Debt discount		31		30		94		89
Debt issue costs		16		17		50		51
Total interest expense	$	283	$	304	$	892	$	907

Schedule Of Long Term Debt Future Principal Payments Year

Our remaining principal payments on the debt as of September 30, 2015 is as follows (in thousands):

Calendar	Principal
Year	Payment
2015	$	598
2016		2,522
2017		2,741
2018		2,979
Total	$	8,840

COMMON STOCK WARRANTS (Tables)

9 Months Ended

Sep. 30, 2015

Stockholders Equity Note [Abstract]

Schedule Of Common Stock Warrant Activity

Our common stock warrant activity during the nine months ended September 30, 2015 and 2014 is shown below:

	Nine months Ended
	September 30,
	2015				2014
			Weighted				Weighted
			Average				Average
	Number		Exercise		Number		Exercise
	(000’s)		Price		(000’s)		Price
Outstanding, beginning		60	$	8.00		431	$	15.75
Issued		-		-		-		-
Exercised		-		-		-		-
Expired		-		-		(371)		17.00
Outstanding, ending		60	$	2.52		60	$	8.00

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details

SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2015

Summary Of Information About Non Vested Stock Options Disclosure Abstract [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

Our share-based compensation expense recognized in the Company’s results of operations comprised the following (in thousands):

	Three months Ended				Nine months Ended
	September 30,				September 30,
	2015		2014		2015		2014
Research and development expense:
Stock options	$	39	$	57	$	117	$	170

General and administrative expense:
Stock options	$	107	$	141	$	293	$	423
Restricted stock units		4		31		51		123
Subtotal	$	111	$	172	$	344	$	546

Total	$	150	$	229	$	461	$	716

Schedule of Share-based Compensation, Stock Options, Activity

Our stock option award activity during the nine months ended September 30, 2015 and 2014 is shown below:

	Nine months Ended
	September 30,
	2015				2014
	Number		Weighted				Weighted
	of		Average		Number of		Average
	Options		Exercise		Options		Exercise
	(000’s)		Price		(000’s)		Price
Outstanding, beginning		911	$	20.7		747	$	24.95
Granted		-		-		-		-
Exercised		-		-		(6)		6.50
Forfeited or expired		(16)		24.50		(6)		18.00
Outstanding, ending		895	$	20.66		735	$	25.15
Options exercisable		779	$	23.21		674	$	26.65

Schedule of Share-based Compensation, Restricted Stock Units Award Activity

A summary of the grants under the RSU Plans consisted of the following (in thousands):

	Nine months Ended September 30,
	2015				2014
			Number of				Number of
	Number		Vested		Number		Vested
	of RSUs		RSUs		of RSUs		RSUs
Outstanding, beginning		29		29		166		166
Granted		42		-		29		-
Distributed		(26)		(26)		(166)		(166)
Vested		-		32		-		22
Forfeited or expired		-		-		-		-
Outstanding, ending		45		35		29		22

EARNINGS PER SHARE ("EPS") (Tables)

9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted

A reconciliation of the numerators and denominators of basic and diluted EPS consisted of the following (in thousands except per share amounts):

	Three months Ended				Nine months Ended
	September 30,				September 30,
	2015		2014		2015		2014
EPS – basic and diluted
Numerator: net loss	$	(2,649)	$	(2,904)	$	(4,073)	$	(10,513)
Denominator:
Common shares		11,653		9,770		10,432		9,769
Vested RSUs		24		14		14		5
Basic and diluted weighted average shares outstanding		11,677		9,784		10,446		9,774
EPS – basic and diluted	$	(0.23)	$	(0.30)	$	(0.39)	$	(1.08)

Excluded securities:
Common shares issuable:
Stock options		895		735		895		735
Nonvested RSUs		10		7		10		7
Common stock warrants		60		60		60		60
Total excluded common shares		965		802		965		802

LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended			0 Months Ended	1 Months Ended	9 Months Ended	0 Months Ended	9 Months Ended
	Mar. 31, 2015	Sep. 30, 2015	Sep. 30, 2015 Settlement Agreement With Par	Sep. 30, 2015 Pfizer Agreement	Jan. 07, 2015 Egalet Agreement	Oct. 31, 2015 Egalet Agreement	Sep. 30, 2015 Egalet Agreement	Oct. 09, 2015 Egalet Agreement Subsequent Event [Member]	Sep. 30, 2015 Minimum Settlement Agreement With Par	Sep. 30, 2015 Maximum Settlement Agreement With Par
License Development and Commercialization Agreement [Line Items]
Percentage of royalty									10.00%	15.00%
Payment for Termination				$ 2,000,000
Patents expiration year			expire between November 2023 and March 2025
Minimum Net Sales Reaching Description							one-time $12.5 million milestone payment when worldwide Oxaydo net sales reach $150 million in a calendar year.
Agreement Termination Notice Description							Egalet may terminate the Egalet Agreement for convenience on 120 days prior written notice, which termination may not occur prior to the second anniversary of Egalets launch of Oxaydo. Termination does not affect a partys rights accrued prior thereto, but there are no stated payments in connection with termination other than payments of obligations previously accrued. For all terminations (but not expiration), the Egalet Agreement provides for the transition of development and marketing of Oxaydo from Egalet to us, including the conveyance by Egalet to us of the trademarks and all regulatory filings and approvals relating to Oxaydo, and for Egalets supply of Oxaydo for a transition period.
Percentage Of Inventory Allowance Reserve	100.00%
Licenses Revenue		250,000			5,000,000
Proceeds from Milestone Payment On Agreement						2,500,000		2,500,000
Retail Related Inventory, Total		$ 260,000

REVENUE RECOGNITION - Additional Information (Detail) (USD $)	3 Months Ended			9 Months Ended		1 Months Ended	9 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Oct. 31, 2015 Egalet Agreement [Member]	Sep. 30, 2015 Allowance for Sales Returns [Member]
Revenue Recognition, Multiple-deliverable Arrangements [Line Items]
Deferred Revenue, Revenue Recognized	$ 95,000
Sales Returns Liability	173,000			173,000
Sales Returns and Allowances, Goods							120,000
Other Revenue, Net	95,000	314,000	0	95,000	0
Royalty Revenue, Total	0		0	0	4,000
Proceeds from Milestone Payment On Agreement						2,500,000
Cost of Revenue, Total		$ 255,000

INVESTMENTS IN MARKETABLE SECURITIES - Summary of Investments in Marketable Securities (Detail) (USD $) In Millions, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Marketable securities:
Corporate bonds - maturing within 1 year	$ 3.6	$ 3.5
Corporate bonds - maturing after 1 year and through March 2017	1.0	2.8
Total marketable securities	11.9	11.3
Exchange-traded funds
Marketable securities:
Total marketable securities	$ 7.3	$ 5.0

INVESTMENTS IN MARKETABLE SECURITIES - Fair Value and Unrealized Gains (Losses) related to the Company’s Available-For-Sale Securities (Detail) (USD $) In Millions, unless otherwise specified	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Available-for-sale:
Cost	$ 11.9	$ 11.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	11.9	11.3
Corporate Bonds
Available-for-sale:
Cost	4.6	6.3
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	4.6	6.3
Exchange-traded funds
Available-for-sale:
Cost	7.3	5.0
Gross Unrealized Gains	0	0
Gross Unrealized Losses	0	0
Fair Value	$ 7.3	$ 5.0

INVESTMENTS IN MARKETABLE SECURITIES - Assets Measured at Fair Value or Disclosed at Fair Value on Recurring Basis (Detail) (USD $) In Millions, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Assets:
Total marketable securities	$ 11.9	$ 11.3
Corporate bonds
Assets:
Total marketable securities	4.6	6.3
Exchange-traded funds
Assets:
Total marketable securities	7.3	5.0
Fair Value, Inputs, Level 1
Assets:
Total marketable securities	7.3	5.0
Fair Value, Inputs, Level 1 \| Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 1 \| Exchange-traded funds
Assets:
Total marketable securities	7.3	5.0
Fair Value, Inputs, Level 2
Assets:
Total marketable securities	4.6	6.3
Fair Value, Inputs, Level 2 \| Corporate bonds
Assets:
Total marketable securities	4.6	6.3
Fair Value, Inputs, Level 2 \| Exchange-traded funds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 \| Corporate bonds
Assets:
Total marketable securities	0	0
Fair Value, Inputs, Level 3 \| Exchange-traded funds
Assets:
Total marketable securities	$ 0	$ 0

INVENTORIES (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Inventory [Line Items]
Raw and packaging materials	$ 0	$ 260
Finished goods	148	44
Total	148	304
Less: reserve for finished goods	(74)	0
Net	$ 74	$ 304

INVENTORIES - Additional Information (Detail) (USD $)	3 Months Ended			3 Months Ended	9 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
INVENTORIES - Additional Information (Detail) (USD $)	Mar. 31, 2015	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2015 Oxaydo product [Member]	Sep. 30, 2015 Oxaydo product [Member]	Sep. 30, 2015 Nexafed products [Member]	Sep. 30, 2014 Nexafed products [Member]	Sep. 30, 2015 Nexafed products [Member]	Sep. 30, 2014 Nexafed products [Member]	Dec. 31, 2014 Nexafed products [Member]
Inventory [Line Items]
Inventory, Raw Materials and Supplies, Gross		$ 0	$ 260,000
Inventory Reserve For Raw Materials	260,000			126,000	260,000
Cost of Goods Sold										220,000
Deferred Revenue, Current		0	353,000							350,000
Inventory Reserve For Finished Goods						$ 27,000	$ 0	$ 74,000	$ 201,000

Property, Plant and Equipment (Detail)	9 Months Ended
Property, Plant and Equipment (Detail)	Sep. 30, 2015
Building and improvements \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Building and improvements \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years
Scientific equipment \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Scientific equipment \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer hardware and software \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer hardware and software \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Machinery and equipment \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Machinery and equipment \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Land and improvements \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	20 years
Land and improvements \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	40 years

Property, Plant and Equipment - Additional Information (Detail) (USD $)	9 Months Ended		12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Utilities Operating Expense, Depreciation and Amortization	$ 1,840,000		$ 1,790,000
Depreciation, Depletion and Amortization, Nonproduction, Total	$ 92,000	$ 90,000

ACCRUED EXPENSES (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Accounts Payable and Accrued Liabilities [Line Items]
Payroll, payroll taxes, and benefits	$ 260	$ 94
Professional services	269	253
Franchise taxes	10	13
Property taxes	13	15
Marketing and promotion	120	61
Non-clinical and regulatory services	57	83
Other fees and services	96	49
Total	$ 825	$ 568

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

DEBT - Additional Information (Detail) (USD $) Share data in Thousands, except Per Share data, unless otherwise specified	0 Months Ended	1 Months Ended	9 Months Ended
	Jan. 07, 2015	Oct. 30, 2015	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014	Dec. 27, 2013
Debt Instrument [Line Items]
Debt instrument principal amount						$ 10,000,000
Debt instrument, interest rate, stated percentage						8.35%
Debt default long term debt percentage						13.35%
Debt Instrument, Maturity Date			Dec. 01, 2018
Debt instrument, fee amount			50,000
Debt consulting placement fee			100,000
Debt related commitment fees and debt issuance costs			231,000
Debt instrument unamortized discount			220,000		281,000
Warrants to purchase common stock			60
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.52
Debt instrument Cash Maintenance	2,500,000
Repayments of Debt	5,000,000		1,160,000	0
Additions To Debt Instrument Unamortized Discount			33,000
Debt Instrument, Periodic Payment			260,000
Debt instrument, periodic payment, principal		1,360,000	1,160,000
Debt Instrument, Interest Rate, Effective Percentage			10.16%
Maximum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8.00		$ 8.00
Minimum [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52		$ 2.52
Warrant
Debt Instrument [Line Items]
Debt instrument unamortized discount			400,000
Warrants to purchase common stock			60
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8.00
After December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage			1.00%
First Revenue Event Occurs
Debt Instrument [Line Items]
Debt instrument periodic payment terms balloon payment to be paid			$ 795,000
Prior To December 27 2015
Debt Instrument [Line Items]
Debt instrument prepayment percentage			2.00%

DEBT - Summary of Debt (Detail) (USD $) In Thousands, unless otherwise specified	1 Months Ended	9 Months Ended
	Oct. 30, 2015	Sep. 30, 2015
Debt
Balance at Dec 31, 2014	$ 8,840	$ 10,000
Principal payments	(1,360)	(1,160)
Classification		0
Balance at Sept 30, 2015		8,840
Debt Discount
Balance at Dec 31, 2014	(220)	(281)
Modification of warrants		33
Amortization expense		94
Balance at Sept 30, 2015		(220)
Debt Issuance Costs
Balance at Dec 31, 2014	(112)	(162)
Additions		0
Amortization expense		50
Balance at Sept 30, 2015		(112)
Net Debt		8,508
Long-term [Member]
Debt
Balance at Dec 31, 2014		8,242
Principal payments		0
Classification		(1,872)
Balance at Sept 30, 2015		6,370
Debt Discount
Balance at Dec 31, 2014		(281)
Modification of warrants		(33)
Amortization expense		94
Balance at Sept 30, 2015		(220)
Debt Issuance Costs
Balance at Dec 31, 2014		(162)
Additions		0
Amortization expense		50
Balance at Sept 30, 2015		(112)
Net Debt		6,038
Current [Member]
Debt
Balance at Dec 31, 2014		1,758
Principal payments		(1,160)
Classification		1,872
Balance at Sept 30, 2015		2,470
Debt Discount
Balance at Dec 31, 2014		0
Modification of warrants		0
Amortization expense		0
Balance at Sept 30, 2015		0
Debt Issuance Costs
Balance at Dec 31, 2014		0
Additions		0
Amortization expense		0
Balance at Sept 30, 2015		0
Net Debt		$ 2,470

DEBT - Interest Expense (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Interest expense:
Term loan	$ 236	$ 257	$ 748	$ 767
Debt discount	31	30	94	89
Debt issue costs	16	17	50	51
Total interest expense	$ 283	$ 304	$ 892	$ 907

DEBT - Long-Term Debt (Detail) (USD $) In Thousands, unless otherwise specified	Sep. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
2015	$ 598
2016	2,522
2017	2,741
2018	2,979
Total	$ 8,840	$ 10,000

EQUITY FINANCING - Additional Information (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	1 Months Ended	9 Months Ended		6 Months Ended
	Apr. 18, 2013	Sep. 30, 2015	Sep. 30, 2015 Common Stock [Member]	Jun. 30, 2015 Placement Agency Agreement [Member]	Jun. 30, 2015 Securities Purchase Agreement [Member]
Equity Financing [Line Items]
Proceeds from sale of common stock	$ 13,000		$ 225
Sale leaseback transaction, transaction costs, financing activities		8
Sale leaseback transaction, net proceeds, financing activities		217
Stock issued during period, shares, new issues			54	1,958	1,958
Share price				$ 0.01	$ 3.90
Proceeds from issuance of private placement				7,000	7,630
Description for repayment of placement agent				paid Roth a cash placement fee equal to 6.5% of the gross proceeds in the Offering
Placement agency reimbursed for expenses				$ 35

COMMON STOCK WARRANTS - Schedule Of Common Stock Warrant Activity (Detail) (Warrant [Member], USD $) In Thousands, except Per Share data, unless otherwise specified	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Warrant [Member]
Number of Options
Number of Options Outstanding, beginning	60	431
Number of Options, Issued	0	0
Number of Options, Exercised	0	0
Number of Options, Expired	0	(371)
Number of Options Outstanding, ending	60	60
Weighted Average Exercise Price
Weighted Average Exercise Price, beginning	$ 8.00	$ 15.75
Issued	$ 0	$ 0
Exercised	$ 0	$ 0
Expired	$ 0	$ 17
Weighted Average Exercise Price, ending	$ 2.52	$ 8.00

COMMON STOCK WARRANTS - Additional Information (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	9 Months Ended
	Sep. 30, 2015
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 2.52
Warrant
Class of Warrant or Right [Line Items]
Common stock warrant exercisable outstanding, shares	60
Common stock Warrant expiration date	December 27, 2020
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 8.00

SHARE-BASED COMPENSATION - Recognition of Share-Based Compensation Expense (Detail) (USD $) In Thousands, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development expense	$ 432	$ 955	$ 1,907	$ 3,674
General and administrative expense	111	172	344	546
Share Based Compensation Expense Recognized In Operations	150	229	461	716
Stock options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Research and development expense	39	57	117	170
General and administrative expense	107	141	293	423
Restricted Stock units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
General and administrative expense	$ 4	$ 31	$ 51	$ 123

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details

SHARE-BASED COMPENSATION - Stock Option Award Activity (Detail) (Stock Option Plan [Member], USD $) In Thousands, except Per Share data, unless otherwise specified	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Stock Option Plan [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options Outstanding, beginning	911	747
Number of Options, Granted	0	0
Number of Options, Exercised	0	(6)
Number of Options, Forfeited or expired	(16)	(6)
Number of Options Outstanding, ending	895	735
Number of Options exercisable	779	674
Weighted Average Exercise Price, beginning	$ 20.7	$ 24.95
Weighted Average Exercise Price, Granted	$ 0	$ 0
Weighted Average Exercise Price, Exercised	$ 0	$ 6.50
Weighted Average Exercise Price, Forfeited or expired	$ 24.50	$ 18.00
Weighted Average Exercise Price, ending	$ 20.66	$ 25.15
Weighted Average Exercise Price, Options exercisable	$ 23.21	$ 26.65

SHARE-BASED COMPENSATION - Summary of RSU Plan (Detail) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Restricted Stock Units [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	29	166
Granted	42	29
Distributed	(26)	(166)
Vested	0	0
Forfeited or expired	0	0
Outstanding, ending	45	29
Vested Restricted Stock Units (RSUs) [Member]
Share based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, beginning	29	166
Granted	0	0
Distributed	(26)	(166)
Vested	32	22
Forfeited or expired	0	0
Outstanding, ending	35	22

SHARE-BASED COMPENSATION - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended		1 Months Ended	9 Months Ended		0 Months Ended	8 Months Ended	9 Months Ended		8 Months Ended			0 Months Ended		1 Months Ended
	Sep. 30, 2014 Stock options [Member]	Sep. 30, 2014 Option Plan [Member]	Jan. 31, 2014 2005 Restricted Stock Unit Award Plan [Member]	Sep. 30, 2015 2005 Restricted Stock Unit Award Plan [Member]	Sep. 30, 2014 2005 Restricted Stock Unit Award Plan [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member]	Sep. 30, 2015 2014 Restricted Stock Unit Award Plan [Member]	May 01, 2014 2014 Restricted Stock Unit Award Plan [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Settled In Cash [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Distributed In Common Stock [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Convertible Common Stock [Member]	Jan. 02, 2015 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	May 01, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Dec. 31, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Sep. 30, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]	Jun. 30, 2014 2014 Restricted Stock Unit Award Plan [Member] Four Non Employee Directors [Member]
Employee Benefit Plans Disclosure [Line Items]
Withholding tax obligations	$ 36
Shares withheld upon elections made to exchange RSUs	4		66
Restricted Stock Units Exchanged In Satisfaction Of Withholding Tax Obligations			500
Number of vested shares distributed to holders			100
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant									400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					165								10	7
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage															25.00%	25.00%	50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Description													stock, for up to 40%	stock, for up to 40%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value															26
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights				one-fourth of vested shares of common stock underlying RSU awards of 0.66 million shares were distributed (after payment of exercise costs of $0.01 par value per share) on January 1 of each of years 2011 thru 2014
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	6	5				26	26			6	26	20
Share Based Compensation Arrangement Share Based Payment Shares Reserved For Future Distribution							4
Stock Issued During Period Shares Stock Options Exercised Net Of Shares For Tax Withholdings		3
Share-based Compensation Arrangement by Share-based Payment Award, Shares Purchased for Award								330
Deferred Compensation Arrangement with Individual, Recorded Liability								$ 33

INCOME TAXES - Additional Information (Detail) (USD $) In Millions, unless otherwise specified	12 Months Ended	9 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2014	Sep. 30, 2015 Federal Research and Development	Dec. 31, 2014 Federal Research and Development	Sep. 30, 2015 Indiana State Research and Development	Dec. 31, 2014 Indiana State Research and Development	Dec. 31, 2014 Maximum	Dec. 31, 2014 Minimum
Income Tax Disclosure [Line Items]
Federal income tax benefits	$ 51.5
Federal NOLs	151.4
U.S. statutory tax rate	34.00%
NOL expiration year						2034	2016
Research and development tax credits			1.1		0.3
Research and development expiration period		which expire for the tax years 2024 through 2034		which expire forthe tax years 2015 through 2017
State income tax benefits	$ 2.9

EARNINGS PER SHARE ("EPS") - Reconciliation of Numerators and Denominators of Basic and Diluted EPS (Detail) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
EPS - basic and diluted
Numerator: net loss	$ (2,649)	$ (2,904)	$ (4,073)	$ (10,513)
Denominator:
Common shares	11,653	9,770	10,432	9,769
Vested RSUs	24	14	14	5
Basic and diluted weighted average shares outstanding	11,677	9,784	10,446	9,774
EPS - basic and diluted	$ (0.23)	$ (0.3)	$ (0.39)	$ (1.08)
Common shares issuable:
Total excluded common shares	965	802	965	802
Stock options
Common shares issuable:
Total excluded common shares	895	735	895	735
Nonvested RSUs member
Common shares issuable:
Total excluded common shares	10	7	10	7
Common stock warrants
Common shares issuable:
Total excluded common shares	60	60	60	60

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

- Definition

This element represents the weighted average total number of shares issued throughout the period including the first (beginning balance outstanding) and last (ending balance outstanding) day of the period before considering any reductions (for instance, shares held in treasury) to arrive at the weighted average number of shares outstanding. Weighted average relates to the portion of time within a reporting period that common shares have been issued and outstanding to the total time in that period. Such concept is used in determining the weighted average number of shares outstanding for purposes of calculating earnings per share (basic).

+ References+ Details

COMMITMENTS AND CONTINGENCIES - Additional Information (Detail) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2015
Pennsylvania State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	200
New Jersey State
Commitments and Contingencies Disclosure [Line Items]
Number of lawsuits filed	150
Number of lawsuits served	50
California State
Commitments and Contingencies Disclosure [Line Items]
Number of plaintiffs served in a single complaint	445
Palatine Lllinois
Commitments and Contingencies Disclosure [Line Items]
Leases administrative office space	$ 25
Lease expiring date	March 31, 2016

DESCRIPTION OF BUSINESS -Additional Information (Detail) (Limitx technology [Member], USD $) In Thousands, unless otherwise specified	14 Months Ended
	Sep. 30, 2015	Aug. 31, 2014
Limitx technology [Member]
Description of Business [Line Items]
Amount Granted for technology development		$ 300
Amount Received from Grant for technology development	$ 237